Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)

Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health Japan, Kitakyushu, Japan; View further author information

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; View further author information

Masayoshi HarigaiDepartment of Epidemiology and Pharmacoepidemiology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan; View further author information

Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan; View further author information

Toshikazu NakanoJanssen Pharmaceutical K.K., Tokyo, Japan; View further author information

Koshiro AkagiJanssen Pharmaceutical K.K., Tokyo, Japan; View further author information

Yoshifumi UkyoJanssen Pharmaceutical K.K., Tokyo, Japan; View further author information

Benjamin HsuJanssen Research & Development, LLC, Spring House, PA, USACorrespondence[email protected]

http://orcid.org/0000-0002-0718-213X View further author information

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Xin Zhao, Chenhao Zhang, Yi An, Zixuan Zhang, Jiahe Zhao, Xinwen Zhang, Yue Yang & Wei Cao. (2023) Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents. Journal of Inflammation Research 16, pages 443-452.
Read now

Articles from other publishers (2)

Theodora Kalpachidou, Lydia Riehl, Clemens L. Schöpf, Buket Ucar & Michaela Kress. (2022) Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain. Pain 163:S1, pages S79-S98.
Crossref

Reyhaneh Sabourian, Seyedeh Zohreh Mirjalili & Nima Rezaei. 2022. Translational Autoimmunity. Translational Autoimmunity 205 242 .

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)

Citations (3)

Read on this site (1)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date